Assessment of NSAID-treated Patients Adherence to Co-prescribed Proton Pump Inhibitor (PPI)

The primary objective of this cross-sectional observational real life study is to investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID associated GI Ulcers to patients prescribed a NSAID. Patients included have Osteoarthritis, Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient questionnaires.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Osteoarthritis Ankylosing Spondylitis Ankylosis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Axial Spondyloarthritis Bone Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Rheumatoid Arthritis Skin and Connective Tissue Diseases Spinal Diseases Spondylarthritis Spondylarthropathies Spondylitis Spondylitis, Ankylosing

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Kristianstad, Sweden

About this study

Cross-sectional, observational Real Life study on NSAIDs treated patients with Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis: Assessment of patient adherence to PPI treatment

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Confirmed diagnosis (documented in the medical record) of OA, RA or AS
Prescription of oral NSAID treatment for OA, RA or AS, where low dose is not sufficient
Prescription of PPI for prevention of NSAID associated GI ulcers, with instruction to take PPI same day as when taking NSAID.

Exclusion criteria

Participating in any clinical trial involving PPI or NSAID
Patients prescribed PPI as acute treatment of GI events or symptoms within 8 weeks
Inability to complete PROs

Treatment and study plan

Primary outcomes

Patient reported adherence to PPI treatment on actual days of NSAID treatment.

Time frame: 7 days

Secondary outcomes

Proportion of patients with reported adherence ≤ 80%.

Time frame: 7 days
Patient adherence to prescribed ASA treatment.

Time frame: 7 days

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Cross-sectional, Observational Real Life Study on NSAIDs Treated Patients With Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis: Assessment of Patient Adherence to PPI Treatment

Acronym: CONVOY

Important dates

Study start: 2012
Primary completion: 2012
Study completion: 2012
First posted: Jan 26, 2012
Registry last updated: May 30, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed